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We describe a case of an 81-year-old male presenting with bitemporal visual field defects and blurry vision in the right eye. &e
patient was found to have a recurrent primary paraganglioma in the sellar and suprasellar region requiring a repeat
transsphenoidal endoscopic resection. Immunohistochemical examination confirmed paraganglioma with the classic zellballen
appearance which stained positive for chromogranin, synaptophysin, and S-100 in the periphery. Paragangliomas (PGLs) in
the sella turcica are a rare entity; only 19 cases have ever been reported in the literature. PGLs in the sellar region are often
misdiagnosed or diagnosed in a delayed fashion. Earlier diagnosis of this locally aggressive tumor and meticulous debulking
can prevent morbidity secondary to the tumor’s compressive effects. &is report highlights the effectiveness of surgical in-
terventions in treatment of paragangliomas. More research is still needed to determine the need for adjuvant therapies such
as radiation.
1. Introduction
Paragangliomas (PGLs) are rare, nonepithelial neuroendo-
crine neoplasms (NENs) [1] that arise from neural crest cells
and generally occur in locations where paraganglia normally
are found [2]. &ere are two main types: parasympathetic
and sympathetic [3]. Parasympathetic are usually in the head
and neck and nonfunctional, while sympathetic are typically
in the thorax, abdomen, retroperitoneum, and pelvis and are
functional [3–5]. &e most well-known type of para-
ganglioma is a pheochromocytoma which originates in the
adrenal medulla [5]. While all PGLs have neurosecretory
granules, those classified as functional secrete catechol-
amines leading to symptoms such as secondary hyperten-
sion, flushing, increased perspiration, headaches, and
tremors [6]. Only 1–3% of PGLs in the head and neck are
functional [7].
In the head and neck, PGLs account for only 0.6% of all
tumors [8]. Of all PGLs, only 3% occur in the head and neck
region [7]. PGLs are found along parasympathetic para-
ganglia of the glossopharyngeal and vagus nerves with the
most common site being the carotid body (75%) and the
second being the temporal bone (16%) [3, 8, 9]. Other sites
such as vagal, laryngeal, subclavian, aorticopulmonary, and
cardiopulmonary are also documented [3].
60–70% of carotid body PGLs present as a nontender,
enlarging mass in the lateral neck often with a bruit and can
lead to cranial nerve IX, XI, and XII deficits [7]. Vagal PGLs
are also nontender, slow growing neck masses in the lateral
neck with the majority at the angle of the mandible.
Symptoms consist of pulsatile tinnitus and in one to two
thirds lower cranial nerve palsies in X, IX, XI, and XII [7].
When PGLs are intracranial, over 90% are from the
temporal bone, in the jugular foramen or middle ear (termed
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tympanic) [10]. Jugular PGLs present as an enlarging mass
around the jugular bulb leading to decreased venous blood
return on that side and resultant rerouting to the contra-
lateral sigmoid sinus [7]. &ese often lead to pulsatile tin-
nitus, an audible bruit over the ear, dizziness, or hearing loss
[7]. Tympanic PGLs typically present as a small mass in the
tympanic membrane or external auditory canal associated
with tinnitus and hearing loss [7]. PGLs generally present as
an enlarging mass with symptoms based on the topographic
location.
Sellar PGL generally presents as an enlarging sellar mass
most often associated with vision loss/impairment and
headaches [11]. To our knowledge, there are only 19 cases
reported of primary sellar paragangliomas. We present a
case of a recurrent paraganglioma of the sellar and supra-
sellar region and compare our findings to the current
literature.
2. Case Presentation
An 81-year-old male with a history of atrial fibrillation on
warfarin, hypertension, and glaucoma initially presented
with progressively worsening blurry vision. On physical
examination, he was found to have visual field defects, with
no other cranial nerve sensory or motor defects. Addi-
tionally, there was no evidence of endocrinopathy or au-
tonomic changes noted.
On radiologic evaluation, the patient was found to have a
sellar mass pressing on the optic chiasm, most consistent
with a pituitary microadenoma. Two years earlier, he un-
derwent a transseptal transsphenoidal resection of the pi-
tuitary tumor at another institution to decompress the optic
chiasm. Histopathological evaluation of the resection had
features of a paraganglioma. Postoperatively, there was no
progression of his visual deficits.
Several months later, the patient presented to our clinic
with worsening visual problems especially blurry vision on
the right side and decreased short-term memory. He also
reported two episodes of epistaxis within the prior ten days.
He denied having any problems with balance or episodes of
headaches. On physical examination, he had decreased
bitemporal fields and an increased right inferior field but can
still see hand movements in both superior quadrants on the
right side. Visual acuity in the left eye was good. &e pupils
were equal, round, and reactive to light. &e extraocular
movements were intact. &e remainder of the physical exam
was unremarkable.
On imaging, MRI demonstrated a lobulated
1.9 cm× 2.1 cm× 2.3 cm T2 hyperintense homogeneous
enhancing mass causing expansion of the sella turcica and
extending into the suprasellar cistern compressing the optic
chiasm and the right optic nerve (Figure 1). &ere was also
extension into the medial aspect of the cavernous sinus.
Transsphenoidal endoscopic resection with intra-
operative MRI and CT stealth stereotactic navigation was
used to extensively decompress the optic nerve and chiasm
and resect the paraganglioma. Intraoperative MRI demon-
strated a gross-total resection of the tumor (Figures 2(a) and
2(b)).
On histopathological evaluation, the tumor displayed
features of a paraganglioma. &e tumor cells were arranged
in relatively well-defined nests (“zellballen”) (Figures 3(a)
and 3(c)) surrounded by a delicate network of reticulin fi-
bers. &ese were highlighted in the sections stained with the
silver impregnation method (Figures 3(b) and 3(d)). Rela-
tively large elongated cells, with clear cytoplasm (principal
cells), were the most prominent component of nests. &e
sustentacular cells were difficult to detect in the routine
stained sections. Only a rare mitotic figure was identified,
and areas of necrosis were not observed. By immunohis-
tochemistry, the tumor cells were positive for synaptophysin
(Figure 4(a)), chromogranin (Figure 4(c)), NCAM (neural
cell adhesion molecule, CD56) (Figure 4(d)), and neuron-
specific enolase (Figure 4(e)). &e sustentacular cells were
strongly immunoreactive for S100 protein (Figure 4(b)).
Focally, the tumor cells were also positive of cytokeratin
(AE1/AE3) (Figure 4(f)). &ey were not immunoreactive for
calretinin or neurofilament protein.
&e patient is currently symptom-free with no recurrent
tumor on repeat imaging 2.5 years after surgery.
3. Discussion
Paragangliomas arise from neural crest cells, but the exact
pathogenesis of sellar PGLs is not completely understood. A
widely accepted hypothesis indicates paraganglionic cells
from cranial nerve IX (tympanic or ciliary branches) migrate
into the cavernous sinus that is just adjacent to the sella
turcica [12].
&e differential diagnosis for sellar tumors is large and
includes pituitary adenomas (85%), craniopharyngiomas
(3%), Rathke cleft cysts (2%), meningiomas (1%), and me-
tastases (0.5%) [13]. Other rare masses such as oncocytomas,
neurohypophysis granular cell tumors, hypophysitis, and
pituicytomas are also seen [14]. Paragangliomas in this
Figure 1: Preoperative sagittal T2-weighted MRI showing
15.41mm by 12.94mm paraganglioma in the sellar and suprasellar
region.
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(a) (b)
Figure 2: Intraoperative T2-weighted MRI: (a) sagittal and (b) coronal views following resection of paraganglioma with the cross-sectional
slice indicated by the vertical lines.
(a) (b)
(c) (d)
Figure 3: Paraganglioma with a distinct nested pattern of the tumor cells (“zellballen”) in sections stained with hematoxylin-eosin (H&E) (a,
c); the nested pattern was highlighted by a silver impregnation for reticulin fibers (b, d). Figures a and b 100x; figures b and c 400x.
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region are an extremely rare diagnosis and often initially
misdiagnosed.
According to a recent literature review, sellar para-
gangliomas are most commonly initially diagnosed as a
pituitary adenoma (77.8%) followed by meningioma, cra-
niopharyngioma, and macroadenoma [11]. Of the 19 other
sellar PGL case reports, 9 were initially misdiagnosed (4 as
adenomas, 2 as meningiomas, 2 as macroadenomas, and 1 as
a craniopharyngioma while 10 other cases did not report on
misdiagnosis) [11]. Our patient was initially misdiagnosed
with a pituitary adenoma.
&e most common presenting symptom for sellar PGLs,
as seen with our patient, is visual disturbances. Of the 19
sellar PGLs, patients’ symptoms on presentation were visual
disturbances/vision loss (63.2%, 12/19), headaches (47.4%,




Figure 4: Strong immunoreactivity in principal cells for synaptophysin (a), chromogranin (c), CD56 (d), and neuron-specific enolase (e).
Sustentacular cells with strong immunoreactivity for S-100 protein (b). Focally, the tumor cells were also positive for AE1/AE3 (cytokeratin)
(f ); figures a–f, 200x.
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19) with each of the following: gait imbalance, amaurosis,
depression, anxiety, amenorrhea, proptosis, conjunctival
vessel dilation, impotence, asthenia, dysthymic disorder,
temporospatial confusion, abnormal behavior, galactorrhea,
confusion, short-term memory loss, progressive lower limb
hyposthenia, vertical nystagmus, arrested growth and sexual
development, and hypopituitarism [11].
&e typical workup, if the patient is suspected to have a
PGL or pheochromocytoma, consists of an MRI or CTof the
abdomen and pelvis, a serum calcitonin level, 24-hour urine
collection to measure catecholamine levels, and plasma-free
fractionated metanephrines [6]. Of head and neck PGLs,
6–19% are malignant [15]. &e diagnosis of malignant
paraganglioma is currently debated. Studies have indicated
that histopathological features (hypervascularity, central
necrosis, and increased mitotic activity) are unreliable in
distinguishing benign from malignant PGLs [2]. &e cur-
rently accepted definition is when the tumor has spread to
other nonendocrine tissues [2, 16].
Since only 1–3% of head and neck PGLs are functional,
they generally do not result in increased catecholamine levels
which cause the elevated blood pressures, flushing, palpi-
tations, and so on [7]. As described in the introduction, most
patients with head and neck PGLs initially present with
symptoms related to mass effect based on topographic lo-
cation or incidental finding on imaging [4]. Carotid and
vagal PGLs present with enlarging masses and lower cranial
nerve palsies [7]. Vagal, jugular, and tympanic PGLs can all
lead to hearing loss and tinnitus [7]. And as seen in our
patient, visual disturbances are the most common initial
presenting symptom in sellar PGLs (65%, 13 of 20 sellar
cases) [11].
&e average age of presentation is the 5th-6th decade for
carotid and jugulotympanic, 5th decade for vagal, and 4th–6th
decade for laryngeal PGLs [17]. Of the 20 sellar cases in-
cluding this report, the average age with standard deviation
was 48.3± 21.1 years with a wide range from 14 to 84 years.
&e female to male ratio is 2 :1 (8 :1 in high altitude) for
carotid, 2:1–8:1 for vagal, 3:1–9:1 for tympanic, and 3 :1 for
laryngeal PGLs [17]. On the contrary, 20 sellar PGLs had a
male predilection with 14 males (70%) and 6 females (30%;
M : F ratio of 2.3 :1). Bilateral and/or multifocal PGLs occur
in 10–25% of carotid, 20–40% of vagal, often with carotid
and/or vagal PGLs for tympanic, and rarely for laryngeal
PGLs [17]. None of the 20 sellar PGLs, including the present
study, were reported to be bilateral or multifocal [11]. &e
metastatic risk also varies by type: 4–6% in carotid, 16% in
vagal (metastatic vs. multifocal was not clear), 2% in tym-
panic, and 2% in laryngeal [17]. Only 1 of the 20 sellar PGLs
(5%) was noted to havemetastasis [14]. Additionally, none of
the 20 sellar PGLs had elevated catecholamine levels [11, 12].
CTand MRI are the most common imaging studies used
in diagnosis with sensitivity of 95–100% and specificity of
67–70% [18]. PGLs enhance on contract CTand gadolinium
MRI [19]. PGLs have low signal on T1-weighted and high
signal on T2-weighted MRI, as seen in our patient’s hy-
perintense homogeneous sellar PGL (Figure 1) [19]. One
classic sign, seen more in head and neck PGLs than those in
the trunk, is a “salt and pepper” appearance composed of
flow voids creating low-signal intensity and hemorrhage
creating hyperintense regions on both T1- and T2-wieghted
MRI [20].&is “salt and pepper” pattern is not seen in any of
the 20 sellar PGLs, but rather sellar PGLs are described as a
well-circumscribed homogeneous or heterogeneous mass
with intense contrast enhancement [12]. Only 2 of the 20
sellar cases described flow voids [14, 21]. Most head and neck
patients have nonfunctional PGLs; thus, biomarker imaging
that is commonly used for functional PGLs of the abdomen
is not always useful [19]. However, if the patient’s head and
neck PGL makes catecholamines, then 3-methoxytyramine
may be used to localize these tumors [19]. Our patient had a
nonfunctional PGL, so biomarker imaging was not utilized.
10–50% of paragangliomas are secondary to a hereditary
condition such as familial paraganglioma, neurofibroma-
tosis type I, von Hippel–Lindau disease, Carney triad, and
occasionally, multiple endocrine neoplasia type 2 (MEN2)
[4]. &e most common genetic mutation with benign par-
agangliomas of the head and neck is the succinate dehy-
drogenase (SDH) mitochondrial complex [17]. &e
mutational status for SDH was not investigated in this case.
For head and neck PGLs, patients with a genetic mutation
most commonly present with a family history, multiple
lesions/malignant, and are 40 years or younger [7].
Diagnosis is made based on histopathology with the classic
description of “zellballen” or nesting of cells surrounded by
abundant capillaries which are found in normal paraganglia
[22]. In the periphery, sustentacular cells stain positive for
S-100 protein [22] which was seen in our patient and is re-
ported to occur in over 50% of the cases in the literature [11]. In
the prior literature, all sellar paragangliomas have been
chromogranin- and synaptophysin-positive as in our patient.
After diagnosis, management of head and neck PGLs
differs based on the type. For functional PGLs or pheo-
chromocytomas, patients will require preoperative blood
pressure managements with alpha-blockers (typically phe-
noxybenzamine) and beta-blockers (propranolol) to avoid
intraoperative hypertensive crisis [18]. Primary treatment is
tumor resection which is widely agreed upon. Carotid PGLs
with SDHB mutations are more likely to develop local/re-
gional recurrence and/or distant metastases and may require
more extensive surgery [23]. Adjuvant therapy with radia-
tion is currently under debate as to improved patient out-
comes. Of the 20 sellar PGLs, 35% (7/20) received radiation
therapy and 25% (5/20) had an additional resection: pter-
ional (10%, 2/20), subfrontal (10%, 2/20), and frontal (5%, 1/
20) [11]. One study found postoperative radiation slowed
progression of residual disease in patients with malignant
PGLs [16]. Additionally, patients with metastatic PGLs may
benefit from chemotherapy to decrease symptoms or for
tumor shrinkage [24]. &e only sellar PGL patient with
metastasis, to the skull and the right femur, underwent
surgery and radiation but not chemotherapy [11].
&ere are limited data on recurrence and overall survival
rates of these patients. Of the 20 sellar patients, all patients
are living at time of follow-up (months to years); however,
many patients have postoperative morbidity with visual
disturbances in 15% (3/20), diabetes insipidus in 15% (3/20),
adrenocortical insufficiency in 5% (1/20), diplopia in 5% (1/
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20), persistent hyposthenia in 5% (1/20), basal ganglion
infarction in 5% (1/20), headaches in 5% (1/20), and hy-
popituitarism in 5% (1/20) [11]. Patients with single-site
PGLs after surgical resection have an equivalent life ex-
pectancy to age-matched disease-free individuals [6].
However, around 30% of patients have recurrence of their
paraganglioma [18]. Patients with familial forms are 3.4
times more likely to have recurrence than those with spo-
radic disease [25]. Of these patients with recurrence, 50%
have had distant metastasis [25]. Follow-up is highly rec-
ommended since many patients have persistence or recur-
rence of disease. Patients should be encouraged to undergo
genetic testing to identify if there is a syndromic link.
Postoperatively, patients should undergo annual surveil-
lance with aMRI or CT to ensure the tumor has not recurred
[6]. Patients with functional PGLs should also undergo
annual biochemical screening [6].
4. Conclusions
While, rare, paragangliomas should be kept on the differ-
ential for a sellar lesion. If there is a high index of suspicion
based on symptoms, family history, elevated catecholamines,
etc., an additional workup should be considered. Surgery is
the mainstay of treatment, with no clear consensus for
adjuvant therapy in the literature.
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